Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with \textsuperscript{123}IBZM-SPECT

J B Schulz, T Klockgether, D Petersen, M Jauch, W Müller-Schauenburg, S Speker, K Voigt, J Dichgans

Abstract
Sixteen patients with a clinical diagnosis of probable multiple system atrophy (MSA) were examined clinically by MRI and by \textsuperscript{123}I-iodobenzamide single photon emission computed tomography (IBZM-SPECT). The clinical records of another 16 patients were also analysed retrospectively. On the basis of their clinical presentation, patients were subdivided into those with prominent parkinsonism (MSA-P, n = 11) and those with prominent cerebellar ataxia (MSA-C, n = 21). Autonomic symptoms were present in all patients and preceded the onset of motor symptoms in 63% of patients. Calculated median lifetime and the median time to become wheelchair bound after onset of disease were significantly shorter for MSA-P than for MSA-C (lifetime: 4.0 ± 9.1 years; wheelchair: 3.1 ± 5.0 years) suggesting a better prognosis for cerebellar patients. A significant loss of striatal dopamine receptors (below 2 SD threshold) was detected by IBZM-SPECT in 63% of the patients (56% below 2.5 SD threshold). There was no difference between patients with MSA-C and those with MSA-P in the proportion with significant receptor loss and the extent of dopamine receptor loss. Planimetric MRI evaluation showed cerebellar and brainstem atrophy in both groups. Atrophy was more pronounced in patients with MSA-C than in those with MSA-P. Pontocerebellar hyperintensities and putaminal hypointensities on T2 weighted MRI were found in both groups. Pontocerebellar signal abnormalities were more pronounced in MSA-C than in MSA-P, whereas the rating scores for area but not for intensity of putaminal abnormalities were higher in MSA-P. MRI and IBZM-SPECT provide in vivo evidence for combined basal ganglia and pontocerebellar involvement in almost all patients in this series.

(J Neurol Neurosurg Psychiatry 1994;57:1047–1056)

The term multiple system atrophy (MSA), first used by Graham and Oppenheimer in 1969,\textsuperscript{1} refers to a sporadically occurring adult onset neurodegenerative disease. Neuropathologically, MSA is characterised by the presence of olivopontocerebellar atrophy, striatonigral degeneration, and degeneration of the intermedialateral cell columns of the spinal cord. All of these changes are not necessarily found in each patient with MSA. In some patients, degeneration affects mainly the basal ganglia, whereas in others the pontocerebellar system or the spinal cord are more affected. Therefore, evidence of cell degeneration and gliosis in at least three of the following anatomical structures is thought to be sufficient for the neuropathological diagnosis of MSA: striatum, substantia nigra, Purkinje cell layer of the cerebellar cortex, pontine nuclei, inferior olives, and intermedialateral cell columns of the spinal cord.\textsuperscript{2,3} Striatum or substantia nigra must be one of these areas.\textsuperscript{4} By contrast with idiopathic Parkinson’s syndrome, there is no Lewy body pathology in MSA. Rather, a recent study had reported the presence of glial cytoplasmatic inclusion bodies in MSA.\textsuperscript{5} The specificity of this finding remains to be proved in further studies.

The clinical presentation of patients with MSA is highly variable, at least at the onset of the disorder: patients may present with parkinsonism, with a cerebellar syndrome, with progressive autonomic failure, or with variable combinations of these syndromes. Usually parkinsonian symptoms respond only poorly to levodopa. Only a minority of patients with MSA are correctly diagnosed during life due to equivocal clinical symptomatology and the lack of definite diagnostic tests. Accordingly, some patients with MSA are simply diagnosed as having Parkinson’s disease. Other patients are categorised under the umbrella terms Parkinson-plus syndrome or atypical parkinsonism. Patients with a combination of parkinsonism and autonomic failure are often referred to as having Shy-Drager syndrome. On the other hand, MSA may be the underlying pathology in patients with prominent cerebellar ataxia who received the diagnosis of sporadic olivopontocerebellar atrophy or idiopathic cerebellar ataxia during life. In an attempt to form a rational basis for the intra vitam diagnosis of MSA, Quinn\textsuperscript{6} proposed clinical criteria for the diagnosis of probable MSA; these include the presence of parkinsonism or cerebellar ataxia and severe symptomatic autonomic failure without dementia and downgaze palsy. Dependent on whether parkinsonian or cerebellar symptoms predominate the diagnosis is parkinsonian (MSA-P) or cerebellar (MSA-C) (probable) MSA.

In recent years, modern imaging methods such as MRI,\textsuperscript{7-11} SPECT,\textsuperscript{12,13} and PET\textsuperscript{14,15} have increasingly been used in neurodegenera-
tive diseases. Although these methods have also been applied to patients with MSA, their diagnostic value in MSA remains uncertain. The reported abnormalities, such as putaminal iron accumulation or loss of dopamine receptors, are found in other parkinsonian syndromes. Also, most studies are restricted to patients with MSA who have parkinsonian symptomatology, whereas patients with cerebellar symptoms have attracted much less attention.

In this study, we report clinical, MRI, and 123I-iodobenzamide (IBZM) single photon SPECT data from a series of 16 patients with probable MSA of either parkinsonian (MSA-P) or cerebellar (MSA-C) type. The aim of the present study was twofold. Firstly, we wished to study the natural history and prognosis of MSA and to compare MSA-C and MSA-P. Secondly, we wished to study the abnormalities detected by MRI and IBZM-SPECT in patients with MSA. In particular, we were interested in whether these imaging procedures can identify abnormalities that are common to all patients with MSA or whether they yield different results in cerebellar and parkinsonian patients.

Patients and methods

Patients

The clinical records of all patients with parkinsonian symptoms (n = 850) and all patients with cerebellar degenerative disease (n = 217) referred to our department between 1983 and 1991 were reviewed. Of these, 32 fulfilled all of the following four diagnostic criteria for probable MSA: (a) progressive cerebellar ataxia and/or non-responsive or poorly responsive levodopa parkinsonism without evidence for a focal or non-focal symptomatic origin of the disorder; (b) severe symptomatic autonomic failure with at least postural syncope or presyncope and/or pronounced urinary incontinence or retention not due to other causes; (c) absence of any neurodegenerative disorders in relatives and no evidence of consanguinity of parents; (d) absence of dementia according to DSM-III-R criteria, generalised tendon areflexia, or predominant downgaze supranuclear palsy. Based on their clinical presentation, patients were subdivided into two groups, one with predominant cerebellar symptoms (MSA-C, n = 21) and another with predominant parkinsonian presentation (MSA-P, n = 11).

16 patients were personally interviewed and clinically examined by one of us (JBS) with a standardised examination procedure. Their mean age was 60-1 (SD 8-3) years. Severity of cerebellar symptoms was rated on a scale ranging from 0 (absent) to 5 (most severe). We also used the Hoehn and Yahr scale and the unified Parkinson’s disease rating scale (UPDRS) for rating the severity of parkinsonian patients, and the Kurtzke EDSS scale for estimation of global disability state. Clinical examination included measurement of blood pressure and heart rate in the supine position and one and five minutes after active standing. Orthostatic reduction in systolic blood pressure of 30 mm Hg or more without a sufficient increase of heart rate was considered orthostatic hypotension. On the day of the clinical investigation MRI and IBZM-SPECT were performed. Two patients in whom MRI could not be performed due to claustrophobia or a metallic implant received a high resolution cranial CT examination.

Those patients with probable MSA who were not seen personally (n = 16) were included only in the outcome evaluation. For these patients, age at onset of first notable motor symptom, clinical type (parkinsonian or cerebellar), duration after onset of motor symptoms until they became wheelchair bound, and age at death were determined from the medical records. In many patients autonomic symptoms antedated motor symptoms by several years. Autonomic symptoms were often vague and of undetermined onset, however, so that it turned out to be impossible to use them for exact temporal definition of onset of disease in the 16 patients studied retrospectively.

MRI

MRI was performed with a 1.5 T superconducting system (Magnetom, Siemens AG, Erlangen, Germany) with a circularly polarised coil. Data were displayed on a 256 × 256 matrix. All patients were investigated by a standard examination programme that included sagittal and axial T1 weighted images (spin echo, TR = 600 ms, TE = 15 ms, slice thickness = 4 mm), and axial proton-density and T2 weighted images (dual spin echo, TR = 2100 ms, TE = 45 + 90 ms). To improve slice profiles two subsequent sets of measurements of each sequence were made, each with an interslice gap of 4 mm. Both sets of measurements together gave a complete series of images without a gap. Special care was taken to position the head and neck symmetrically in the head coil. Twenty-four age and sex matched healthy persons served as controls (mean age 58-0 (15-6) years).

Neurological examination of these persons was normal and routine evaluation of their MRIs gave no pathological findings.

Quantitative MRI evaluation of cerebellum, pons, brainstem, and spinal cord was performed under blinded conditions. Regions of interest of any form, location, and size could be outlined with a computer program (fig 3). For quantitative planimetric evaluation of areas we used an image analyser and a computerised interpretation program. This technique permits measurements of the amount of tissue within a region of interest without lining out the border between tissue and CSF by hand. Furthermore, it takes into account partial volume effects that often occur at the surface of the cerebellum. For each case the individual signal intensities of CSF and of the cerebellar tissue were defined.

Those measurements gave two sets of normal distributed brain tissue and CSF grey values. Pixels with values equal or higher than the
mean tissue value were counted as tissue, whereas pixels with values equal or lower than the mean CSF value were counted as CSF. The remaining pixels were designated as containing both tissue and CSF. It was assumed that the difference in signal intensity between grey and white matter could be ignored for this purpose. Those voxels with signal intensities between the mean values of brain tissue and CSF were linearly weighted according to their tissue content. This allowed us to finally summarise the number of effective tissue pixels and to obtain corrected planimetric values for cerebellar structures (see fig 3). To compensate for individual variations in head size we measured the total area of the posterior fossa on the midsagittal slice and related each planimetric measurement to the respective posterior fossa area. There were no statistically significant differences in the area of the posterior fossa between controls and patients with MSA (mean (SD); controls 4922 (379) pixels; MSA-P 4910 (445) pixels; MSA-C: 4834 (480) pixels).

The areas of the cerebellar vermis and the basis pontis were measured on the midsagittal slice. As we obtained a complete series of images without a gap, the midsagittal slice was easily identifiable by showing the cerebral aqueduct in its complete craniocaudal extent. The basis pontis was delineated as an elliptical structure: the ventral border was obvious and the dorsal border was determined by the medial lemniscus, which appeared as a narrow strip of reduced signal intensity. The areas of the cerebellar hemispheres were calculated on the first parasagittal slice lateral to the lateral border of the middle cerebellar peduncle. As there were no systematic size differences between the hemispheres of the two sides, we calculated the mean of both sides for further analysis. We also measured the area of medulla oblongata in the horizontal plane at the level of the inferior olivary complex and the cervical spinal cord on the horizontal plane at the level of the dens. Also the diameter (mm) of the middle cerebellar peduncle was measured in a horizontal plane with a distance algorithm.

The degree of cortical atrophy and the severity of signal abnormalities on T2 weighted images were rated independently by two of us (JBS, DP). To ensure uniform and anonymous quality of the images, all images were documented on x ray films without any identification data. The degree of cortical atrophy and hypointensities of the putamen, pallidum, substantia nigra, and red and cerebellar dentate nucleus were rated on a scale ranging from 0 to 3. Grade 0 indicated complete absence, grade 1 mild, grade 2 moderate, and grade 3 strong atrophy or hypointensity respectively. The area of signal hypointensity in the putamen was also rated. Grade 0 indicated no hypointensity, grade 1 hypointensity limited to the lateral margin of the putamen, grade 2 hypointensity extending through part of the body of the putamen, and grade 3 hypointensity throughout the entire putamen.11 Hyperintensities of the pons and middle cerebellar peduncles22 were rated to be absent (grade 0), mild (grade 1), moderate (grade 2), or strong (grade 3).

SPECT
IBZM-SPECT was performed two hours after intravenous injection of 185 MBq 123IBZM (3-iodo-6-methoxybenzamide; Cygne BV, Netherlands/Du Pont de Nemour, Germany). If patients were taking medication, this was stopped 24 hours before SPECT scanning. SPECT data were acquired with a dual head rotating gamma Camera (Picker Digital Dyna, AP Collimator) and a PCS 512 computer system (gamma 11). For data acquisition the following standard programme was used: two complete circles (360° each camera head), 64 frames/circle, 64 × 64 matrix, slice thickness 5-5 mm, pixel resolution 5.5 mm, full width at half maximum (FWHM) of the reconstructed line spread function 20 mm. The acquisition time was 40 s/frame.

We superimposed MRI and SPECT with external landmarks. The orbital meatal line, as shown by a laser system on the SPECT system, was marked by a pencil line and oil filled tubes. This line represents the collimator midline and the first MRI image. After prefiltering the raw data (METZ filter) and overlaying a RAMP filter, SPECT reconstruction was done for axial, coronal, and sagittal slices including attenuation correction with an attenuation coefficient of 0.139 cm⁻¹. Images from MRI (256 × 256, 16 bit count depth) were transmitted via ethernet, converted into gamma 11 file format (256 × 256, 8 bit count depth), and internally reduced to 128 × 128 (8 bit count depth) for further procedures. After landmark based slice identification and scale adaptation by zooming, the in plane matching was done under visual control, with a region of interest contour shifting as an intermediate step. To identify the correct anatomical sites axial SPECT and MRI images were superimposed adding then to two to three consecutive SPECT images. On these sum images, basal ganglia and prefrontal regions of interest were drawn. The size of the regions of interest varied from patient to patient and ranged from 20 to 30 pixels (6 to 9 cm²). Care was taken that the striatal region of interest, which had an elongated shape, was clearly within the borders of the striatum, as shown by the superimposed MRI, and that the striatal and prefrontal regions of interest of an individual patient had comparable sizes. The prefrontal region of interest had a band-like shape following isocontours. The regions of interest were used for calculating counts per pixel in the basal ganglia and prefrontal cortex. The ratio of these values (BG/FC ratio) then represents a semiquantitative measure of the relative density of basal ganglia dopamine receptors labelled by IBZM.25

Because we did not obtain the permission of the local ethics committee to perform IBZM-SPECT in healthy controls, we compared the results of the patients with MSA with a group of untreated de novo patients with idiopathic Parkinson's syndrome (Hoehn
and Yahr stage I and II; mean age 53-8 (10-0) years). All patients with idiopathic Parkinson’s syndrome underwent an apomorphine test and were subsequently treated with levodopa. Only those patients were included who had a positive apomorphine test and showed pronounced clinical improvement after a three month treatment with levodopa.

We believe that it is justified to use levodopa responsive patients with idiopathic Parkinson’s syndrome as controls because two earlier studies\(^{13,15}\) failed to show any differences of the BG/FC uptake ratios of IBZM in healthy persons and untreated patients with idiopathic Parkinson’s syndrome. Moreover, the BG/FC ratio (1·76 (SD 0·11)) in our idiopathic Parkinson’s syndrome group was identical to that reported by Brucke and colleagues\(^{19}\) in their healthy controls.

### Results

Eleven out of 32 patients with MSA were women and 21 were men. The mean age at the onset of motor symptoms was 54·1 (SD 7·1); range 40 to 66 years), with no differences between the subgroups (MSA-C 52·8 years; MSA-P 55·7 years). The calculated median lifetime\(^{16}\) after onset of motor symptoms was 8·9 years. It was significantly shorter in MSA-P (4·0 years) than in MSA-C (9·1 years; fig 1A). Similarly, the calculated median time to become wheelchair bound was shorter in MSA-P (3·1 years) than in MSA-C (5·0 years; fig 1B).

Tables 1 and 2 give the clinical data of the 16 personally examined patients. The mean duration of motor symptoms was shorter in MSA-P (mean (SD) 3·0 (2·1) years) than in MSA-C (6·6 (2·6); p < 0·05). All patients had dysautonomia. The most frequent autonomic symptoms were orthostatic hypotension (94%), and urinary incontinence or retention (94%). All male patients complained of erectile dysfunction. Another common sign was vocal cord dysfunction (81%) with nocturnal stridor or hoarseness. Three patients required tracheotomy. In one patient a combined cen-

### Table 1 Clinical data of personally examined patients

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age of onset (y)</th>
<th>First symptom</th>
<th>Duration of symptoms (y)</th>
<th>MO</th>
<th>AF</th>
<th>Paralysis symptoms</th>
<th>Cerebellar symptoms</th>
<th>Pyramidal signs</th>
<th>Kurtzke score</th>
<th>Levodopa response</th>
<th>Treatment at the time of IBZM-SPECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSA with predominant parkinsonian symptoms (MSA-P):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>43</td>
<td>Erectile dysfunction</td>
<td>6</td>
<td>HRS</td>
<td>AS and G</td>
<td>Yes</td>
<td>3</td>
<td>0</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>56</td>
<td>VCP</td>
<td>2</td>
<td>HRS</td>
<td>AS and G</td>
<td>Yes</td>
<td>2</td>
<td>0</td>
<td>Poor</td>
<td>LD 375, Dep, Bron</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>59</td>
<td>Erectile dysfunction</td>
<td>2</td>
<td>HRS, Tr</td>
<td>AS and G, AL</td>
<td>No</td>
<td>4</td>
<td>0</td>
<td>Poor</td>
<td>LD 375, Dep, Mem</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>66</td>
<td>Erectile dysfunction</td>
<td>20</td>
<td>HRS, Tr</td>
<td>AS and G, AL</td>
<td>No</td>
<td>4</td>
<td>0</td>
<td>Poor</td>
<td>LD 375, Dep, Mem</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>58</td>
<td>Urinary dysfunction</td>
<td>5</td>
<td>HRS, AC</td>
<td>No</td>
<td>Yes</td>
<td>9</td>
<td>0</td>
<td>Poor</td>
<td>LD 625, Dep, Lis</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>59</td>
<td>Bradykinesia</td>
<td>4</td>
<td>HRS, AC</td>
<td>No</td>
<td>No</td>
<td>9</td>
<td>5</td>
<td>Poor</td>
<td>LD 560, Dep, Lis</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>59</td>
<td>Erectile dysfunction</td>
<td>10</td>
<td>HRS</td>
<td>AS and G, AL</td>
<td>No</td>
<td>9</td>
<td>5</td>
<td>Poor</td>
<td>LD 375, Dep, Mem</td>
<td></td>
</tr>
<tr>
<td>MSA with predominant cerebellar symptoms (MSA-C):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>59</td>
<td>Erectile dysfunction</td>
<td>4</td>
<td>No</td>
<td>AS and G, AL</td>
<td>Yes</td>
<td>3</td>
<td>5</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>49</td>
<td>Sleep apnoea syndrome</td>
<td>6</td>
<td>No</td>
<td>AS and G, AL</td>
<td>No</td>
<td>6</td>
<td>0</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>55</td>
<td>AS and G</td>
<td>7</td>
<td>HRS</td>
<td>AS and G, AL</td>
<td>No</td>
<td>7</td>
<td>5</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>51</td>
<td>AS and G</td>
<td>1</td>
<td>HRS</td>
<td>AS and G, AL</td>
<td>No</td>
<td>5</td>
<td>0</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>44</td>
<td>AS and G</td>
<td>6</td>
<td>No</td>
<td>AS and G, AL</td>
<td>Yes</td>
<td>7</td>
<td>0</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>40</td>
<td>Erectile dysfunction</td>
<td>8</td>
<td>No</td>
<td>AS and G, AL</td>
<td>Yes</td>
<td>8</td>
<td>5</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>56</td>
<td>VCP</td>
<td>10</td>
<td>HRS</td>
<td>AS and G, AL</td>
<td>No</td>
<td>8</td>
<td>0</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>62</td>
<td>AS and G</td>
<td>3</td>
<td>HRS</td>
<td>AS and G, AL</td>
<td>No</td>
<td>9</td>
<td>0</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>59</td>
<td>AS and G</td>
<td>10</td>
<td>HRS, Tr</td>
<td>AS and G, AL</td>
<td>Yes</td>
<td>9</td>
<td>0</td>
<td>NT</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

VCP = vocal cord paralysis; AS and G = ataxia of stance and gait; MO = motor; AF = automatic failure; HRS = hypokinetic-rigid syndrome; Tr = tremor; AC = antecollis; AL = ataxia of limbs; NT = not tested; LD = levodopa + dopa decarboxylase inhibitor (daily dose in mg); Dep = L-depenil; Bron = bromocriptine; Lis = lisuride; Mem = memantine.
Multiple system atrophy

Table 2 Details of autonomic failures in personally examined patients

<table>
<thead>
<tr>
<th>Case</th>
<th>Orthostatic hypotension</th>
<th>Erectile dysfunction</th>
<th>Urinary dysfunction</th>
<th>Stridor</th>
<th>Anhidrosis</th>
<th>Diarrhoea</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+</td>
<td>Yes</td>
<td>R, I</td>
<td>NS</td>
<td>No</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>Yes</td>
<td>R, SUC</td>
<td>T</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>+</td>
<td>Yes</td>
<td>R, I</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>+ +</td>
<td>Yes</td>
<td>R, I, SUC</td>
<td>T +</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>+ +</td>
<td>*</td>
<td>R, I, SUC</td>
<td>T</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>+ +</td>
<td>Yes</td>
<td>R, I, SUC</td>
<td>T +</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>+ +</td>
<td>Yes</td>
<td>R, I, SUC</td>
<td>T +</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>+</td>
<td>Yes</td>
<td>R</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>9</td>
<td>+</td>
<td>*</td>
<td>I</td>
<td>SAD</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>10</td>
<td>+</td>
<td>Yes</td>
<td>R</td>
<td>NS</td>
<td>No</td>
<td>+</td>
</tr>
<tr>
<td>11</td>
<td>No</td>
<td>Yes</td>
<td>R, SUC</td>
<td>+</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12</td>
<td>No</td>
<td>Yes</td>
<td>I</td>
<td>+</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>13</td>
<td>+ +</td>
<td>Yes</td>
<td>R, SUC</td>
<td>+</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>14</td>
<td>+</td>
<td>*</td>
<td>I</td>
<td>T</td>
<td>+</td>
<td>No</td>
</tr>
<tr>
<td>15</td>
<td>+ +</td>
<td>Yes</td>
<td>R, I, SUC</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>16</td>
<td>+</td>
<td>*</td>
<td>I, SUC</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Orthostatic hypotension: (+) = orthostatic reduction in systolic blood pressure by 30 mmHg or more, + = symptomatic hypotension with presyncope, ++ = symptomatic hypotension with syncope; erectile dysfunction: * = female patient; urinary dysfunction: R = retention, I = incontinence, SUC = suprapubic urinary catheter; stridor: NS = nocturnal stridor, T = tracheotomy after bilateral vocal cord paralysis, SAS = symptomatic hypotension.

Motor symptoms occurred in various combinations. Ten patients had a combination of parkinsonian and cerebellar features (63%), seven without (44%) and three with pyramidal signs (19%). Three patients had cerebellar and pyramidal symptoms without parkinsonism (19%). A pure cerebellar syndrome, pure parkinsonism, or a combination of parkinsonism and pyramidal signs occurred in one patient each. In all patients with MSA-P, the first motor symptom was bradykinesia, in all patients with MSA-C it was ataxia of stance and gait. The first motor symptom, whether parkinsonian or cerebellar, determined the clinical type during the entire course of the disease.

In 10 patients (63%) symptoms of dysautonomia preceded motor signs (table 2), in some of them by more than 10 years. In the remaining six patients in whom the disease started with parkinsonism or ataxia, autonomic symptoms occurred within one to eight years after the onset of motor symptoms. The serial order in which autonomic symptoms occurred was random. Autonomic symptoms were similar in both groups and their duration did not differ significantly between groups (mean (SD) MSA-P 6.6 (6.7) years; MSA-C 5.1 (2.8) years). The orthostatic reduction in systolic blood pressure was more pronounced in MSA-P (mean (SD) 50 (24) mmHg) than in MSA-C (37 (17) mmHg; p = 0.25), but the difference did not reach significance.

IBZM-SPECT

The BG/FC ratio, which serves as a semiquantitative measure of dopamine receptor binding in the striatum, was significantly reduced in MSA (1.50 (0.16) compared with idiopathic Parkinson's disease (1.76 (0.10)). There were no differences between MSA-C (1.49 (0.14) and MSA-P (1.52 (0.20). Three of the seven patients with MSA-P and seven of the nine patients with MSA-C had BG/FC ratios that were more than 2 SD below the normal range (fig 2). If a threshold of 2.5 SD was chosen, three patients with MSA-P and only six with MSA-C were outside the normal range. The BG/FC ratios showed a weak, negative correlation with the Kurtzke score (r = -0.49; p = 0.05), but no significant correlation with the scores rating severity of parkinsonism. They were not significantly correlated with the rating scores for putaminal hypointensities.

MRI

All measures of cerebellar and brainstem size (fig 3) were significantly different by analysis of variance between the patient and control groups (cerebellar vermis: F2,16 = 58.7, hemispheres: F2,16 = 36.7, middle cerebellar peduncle: F2,16 = 79.6, basis pontis: F2,16 = 57.2, medulla oblongata: F2,30 = 20.7; p < 0.0001), whereas there were no differences in spinal cord size and the estimated degree of cortical atrophy (controls: median 0, range 0 to 2; MSA-P 0-5, range 0 to 1; MSA-C 0, range 0 to 2). Further analysis of different main effects by Duncan's multiple range test showed that the size of cerebellar and brainstem structures was reduced in the MSA-P and MSA-C groups compared with controls (p < 0.001) and that the amount of reduction was greater in MSA-C than in MSA-P (fig 4).

On average, the middle cerebellar peduncle showed the most pronounced size reduction of all infratentorial brain structures (fig 3). Its diameter was reduced by more than 2 SD compared with controls in all but two patients

Figure 2  IBZM binding as detected by SPECT in idiopathic Parkinson's syndrome (IPS), MSA-C, and MSA-P. BG/FC ratio = basal ganglia to frontal cortex ratio of IBZM binding. Solid line represents mean of IPS group, dashed line 2 SD. Filled symbols represent individual patients with MSA-C without parkinsonism (n = 4) or patients with MSA-P without ataxia (n = 2) respectively.
with MSA. The diameter was negatively correlated with the Kurtzke score \(r = -0.71; p = 0.004\); there was no correlation with BG/FC ratios of IBZM-SPECT or rating scores for putaminal hypointensities.

Analysis of the degree \(H_{1,27} = 10.4\) and area \(H_{1,27} = 8.4\) of putaminal hypointensities identified the presence of significant group effects \(p < 0.01\). The rating scores for the degree of putaminal hypointensities in MSA-C (median 2, range 1 to 3) and MSA-P (median 2, range 2 to 3) were significantly higher than those of controls (median 0, range 0 to 2; \(p < 0.05\); figs 5 and 6A). The area of the hypointensities was greater in MSA-P (median 2, range 1 to 3) than in MSA-C (median 1.5, range 1 to 2; \(p < 0.05\); fig 6B) and both groups differed significantly from controls (median 0, range 0 to 2; \(p < 0.05\)). No significant differences in the signal intensities of the pallidum, red nucleus, substantia nigra, or dentate nucleus were noted. Putaminal hypointensity exceeding hypointensity of the pallidum has been proposed as an easily accessible indicator of putaminal abnormality. This was true in 12 of 14 patients with MSA, but also in five of 14 control subjects. The rating scores of putaminal hypointensities were not correlated with the Kurtzke scale, the diameter of the middle cerebellar peduncle, or the BG/FC ratio from IBZM-SPECT.

Significant group effects \(p < 0.001\) for hyperintensities within the pons \(H_{1,27} = 16.5\) and middle cerebellar peduncle \(H_{1,27} = 21.0\) were identified. Subsequent mean contrasts showed that both patient groups had higher scores than controls and that patients with MSA-C had higher scores than patients with MSA-P (figs 6B and 7).

**Discussion**

MSA is principally a neuropathological entity encompassing striatonigral degeneration, olivopontocerebellar atrophy, and degeneration of the intermediolateral cell columns of the spinal cord. Clinically patients with MSA present with severe symtomatic autonomic failure and parkinsonian or cerebellar symp-
somes. This has led to the clinical distinction between striatonigral degeneration (parkinsonian) and olivopontocerebellar atrophy (cerebellar) type. A major problem in clinical studies of MSA is the uncertainty of the clinical diagnosis. A definite neuropathological diagnosis was made in only two of our patients who died in the course of the study. Although we have used stringent clinical inclusion criteria, some of our patients may have other degenerative diseases. For example, parkinsonism in combination with autonomic failure may also occur in idiopathic Parkinson’s disease. On the other hand, patients with cerebellar ataxia or parkinsonism without severe dysautonomia were not included in the present study although they may have unrecognised MSA.

Most recent studies of MSA come from researchers with a special interest in Parkinson’s disease. This has probably led to an over-representation of patients with parkinsonian MSA in clinical and neuropathological studies of patients with MSA. In the present study, both patients with predominant parkinsonian and predominant cerebellar features were included allowing us to compare their clinical characteristics, prognosis, and results of imaging procedures.

In all patients, the initial motor symptom, whether parkinsonian or cerebellar, determined the clinical type in the entire course of the disease. Nevertheless, with disease progression an overlap of parkinsonian and cerebellar symptoms occurs. Pyramidal symptoms may add to the complex clinical picture in MSA, but are usually not predominant features. By taking a detailed autonomic history we found that autonomic symptoms, in particular erectile dysfunction, preceded the onset of motor symptoms in more than 60% of our patients, in some of them by more than 10 years. Although it is impossible to prove that these often vague autonomic symptoms occurred as a result of neuronal degeneration in the context of MSA, this finding suggests that MSA may have a presymptomatic phase of several years.

In a review of 213 pathologically established cases of MSA Quinn reported a median survival after onset of first symptoms of five to six years, whereas we found a longer survival of about nine years in our patients. Possible explanations for the difference between the study of Quinn and the present one is that all of Quinn’s patients were diagnosed by pathology, whereas we may have included patients with different disorders, such as idiopathic Parkinson’s disease. It is also difficult to pinpoint precisely onset of disease in many patients. More important is the finding that calculated median lifetime and the median time to become wheelchair bound were significantly shorter in MSA-P than MSA-C. These results imply that the prognosis is better in MSA-C than in MSA-P and justify the division into MSA-C and MSA-P at least for clinical and prognostic purposes. The reasons why parkinsonian patients have a worse prognosis are unclear. Possibly, parkin-
Figure 7  MRI (T2 weighted spin echo images 1·5T, TR = 2100 ms, TE = 45 + 90 ms, slice thickness = 4 mm) of upper pons (left side) and middle cerebellar peduncles (right side). The upper panel shows images of a 53 year old healthy male without signal abnormalities. The lower panel shows hyperintensities of the transverse pontine fibres between segmentsum and the base of pons (left) and in the middle cerebellar peduncles (right) in a 53 year old female patient with MSA-C.

Dopaminergic symptoms and the more severe orthostatic hypotension in patients with MSA-P are the cause of earlier immobility.

Loss of striatal neurons is an integral part of the degenerative process in MSA.1432 Dopamine D2 receptors are located on striatal interneurons and on a subset of striatal projection neurons, mainly on those projecting to the external pallidal segment.33 Loss of these receptors may thus be taken as an indicator of degeneration of these striatal neurons. Dopamine D3 receptors are imaged by IBZM-SPECT.1223 Pharmacologically, IBZM is a specific dopamine D3 antagonist with high affinity for the receptor. Experimental studies in animals show that IBZM binds to areas in the brain with high concentrations of dopamine D3 receptors.2534 Both in animals and in humans, IBZM can be displaced from its binding sites by compounds that are known to specifically interact with dopamine D2 receptors.3334 Reduction of striatal IBZM binding should thus reflect a loss of striatal dopamine D2 receptors. By contrast with PET, however, the IBZM-SPECT method yields only semiquantitative data and the sensitivity of the method has not yet been clearly determined. Also, we need to consider whether the medication of our patients interfered with tracer binding. We believe that this is unlikely because medication was stopped 24 hours before SPECT scanning, allowing adequate time for dopaminergic drugs to leave the synaptic cleft.3536 A further consideration is whether our SPECT results are altered by regional atrophy of the striatum or the prefrontal cortex. Our method of data evaluation leads to an estimation of the relative density of striatal receptors labelled by IBZM (as compared with the prefrontal cortex) rather than to an estimation of total basal ganglia radioactivity. Therefore, shrinkage of the striatum itself would not lead to a reduced BG/FC ratio. On the other hand, cortical atrophy would lead to an underestimation of the FC value and an overestimation of the BG/FC ratio. This is improbable in our patients because the MRIs suggest that there is no significant degree of cortical atrophy in patients with MSA. This is in accord with neuropathological findings showing that degeneration of the cerebral cortex is not a typical neuropathological feature of MSA.37

Although there was a statistically significant reduction of IBZM binding in patients with MSA compared with controls, only 63% of our patients had BG/FC ratios that were more than 2 SD below the normal ratio (56% below the 2·5 SD threshold). These results closely correspond to those of postmortem receptor binding studies3738 and to a recent PET study of MSA using 11C-raclopride to label dopamine receptors.39 Although only patients with parkinsonian MSA were included in this study the authors found a modest reduction of D2 receptor binding. We found, surprisingly, that the proportion of patients with pathological IBZM-SPECT and the extent of receptor loss were not different between MSA-C and MSA-P and were sometimes greater in MSA-P. In particular, individual patients without any parkinsonian symptoms may have a pathological BG/FC ratio in IBZM-SPECT, whereas IBZM binding may be normal in other patients with predominant parkinsonism. These findings indicate that striatal degeneration occurs in patients with MSA independently of their clinical presentation.

It is well known that an extensive loss of striatal neurons, as in the late stages of Huntington’s disease, may lead to parkinsonian symptoms. The moderate extent of receptor loss in MSA and the lack of difference between parkinsonian and cerebellar patients suggest that loss of D2 receptors alone does not explain the occurrence of parkinsonian symptoms in MSA. Indeed, Brooks and colleagues40 have reported significantly reduced striatal uptake of the positron emitting tracers 18F-dopa and 11C-nomifensine, which are markers for dopamine storage capacity and integrity of dopamine uptake sites respectively. Also, a recent PET study reported a moderate loss of D2 receptors in the striatum of patients with striatonigral degeneration.39

Neuropathological studies show that the pallidal nuclei also undergo severe degeneration in MSA,4 which can result in parkinsonian symptoms.41 These findings suggest that the development of parkinsonism poorly responsive to levodopa in MSA is due to widespread neuronal degeneration within the basal ganglia rather than to the loss of a single popula-
tion of neurons as in idiopathic Parkinson’s syndrome.

Abnormalities on MRI in MSA include infratentorial atrophy and signal abnormalities on T2 weighted images within the putamen and the pontocerebellar system. The infratentorial atrophy in MSA affects the cerebellar vermis, cerebellar hemispheres, middle cerebellar peduncles, pons, and lower brainstem. This pattern of macroscopic changes closely corresponds with the changes described in neuropathological studies of olivopontocerebellar atrophy.41 With the same technique of in vivo morphometric evaluation we found similar changes in patients with autosomal dominant cerebellar ataxias.43 Thus olivopontocerebellar atrophy is not a specific morphologic finding in MSA. The infratentorial atrophy in MSA is associated with signal hyperintensities within the pons and middle cerebellar peduncles. These abnormalities, which were first described by Savoiardo et al42 in a heterogeneous group of cerebellar patients, most probably reflect degeneration of pontocerebellar fibres. These fibres originate in the pontine nuclei, cross the midline by taking a transverse course within the pons, and ascend within the contralateral middle cerebellar peduncle. Our finding that infratentorial signal abnormalities are restricted to this fibre tract, and that the middle cerebellar peduncles exhibit the largest size reduction, are strong evidence that the degeneration of the pontocerebellar tract represents the core pathology of olivopontocerebellar atrophy.

Several authors have described the occurrence of putaminal hypointensities in patients with parkinson plus syndromes.4-10 12 15 26 These abnormalities are usually ascribed to accumulation of iron, although this view has been questioned by Brooks and colleagues.46 The finding that putaminal hypointensities occur in patients with parkinson plus syndromes with poor response to dopaminergic drugs has led to the suggestion that these changes reflect damage to postsynaptic striatal dopamine receptors. The lack of correlation between putaminal MRI abnormalities and IBZM binding, however, contradicts this view. By contrast, our findings suggest that putaminal iron accumulation and loss of striatal dopamine receptors represent pathological processes that are independent of each other.

The topography of MRI abnormalities was related to the clinical symptomatology. Quantitative and semiquantitative MRI evaluation gave significant differences between the MSA-P and the MSA-C groups. Putaminal hypointensities were more pronounced in patients with predominant parkinsonism, whereas infratentorial atrophy and pontocerebellar hyperintensities were more severe in patients with predominant cerebellar ataxia. Putaminal or infratentorial MRI changes were, however, not confined to one group of patients. There were patients without obvious parkinsonian signs who had pronounced putaminal hypointensity; on the other hand, infratentorial atrophy or pontocerebellar hyperintensities were present in patients with

out any cerebellar signs. In particular, shrinkage of the middle cerebellar peduncles was found in all cerebellar patients and in all but two parkinsonian patients. In a pathological study, Fearney and Lees4 found pontocerebellar involvement in seven out of 10 cases of striatoniqral degeneration. In the remaining three, cell counts of the cerebellar cortex and pontine nuclei were in the low normal range. The present finding of distributed imaging abnormalities in patients with MSA—indeed, of their clinical presentation—supports the concept that striatoniqral degeneration and (sporadic) olivopontocerebellar atrophy are closely interrelated and should be combined under the heading of MSA.

It would be desirable to complement clinical criteria for the diagnosis of MSA by imaging criteria that help to differentiate MSA from other movement disorders. By the neuropathological definition of MSA1 3-7 11 these criteria should include imaging abnormalities within both the basal ganglia and the pontocerebellar system. Unfortunately, imaging procedures to visualise spinal cord involvement in MSA have not yet been developed. The present data show that single criteria, such as pronounced putaminal hypointensity, decreased IBZM binding, or cerebellar atrophy, may not be specific. Further studies may show whether a particular combination of imaging criteria will lead to improved diagnosis of MSA.

7 Quinn N. Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52 (special supplement):78-89.


Quik M, Spokes E, MacKay A, Bannister R. Alterations in [1H]risperidone binding in human caudate nucleus, substan

Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.

J B Schulz, T Klockgether, D Petersen, M Jauch, W Müller-Schauenburg, S Spieker, K Voigt and J Dichgans

J Neurol Neurosurg Psychiatry 1994 57: 1047-1056
doi: 10.1136/jnnp.57.9.1047

Updated information and services can be found at:
http://jnnp.bmj.com/content/57/9/1047

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/